Israel Discount Bank of New York Has $776,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Israel Discount Bank of New York lifted its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,370 shares of the company’s stock after purchasing an additional 69 shares during the quarter. Israel Discount Bank of New York’s holdings in Johnson & Johnson were worth $776,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. Palisade Capital Management LLC NJ boosted its stake in Johnson & Johnson by 0.3% in the 1st quarter. Palisade Capital Management LLC NJ now owns 93,141 shares of the company’s stock valued at $16,507,000 after buying an additional 250 shares in the last quarter. Lmcg Investments LLC acquired a new stake in Johnson & Johnson in the 1st quarter valued at $12,462,000. Capital Wealth Planning LLC boosted its stake in Johnson & Johnson by 14.0% in the first quarter. Capital Wealth Planning LLC now owns 916,575 shares of the company’s stock worth $162,445,000 after purchasing an additional 112,890 shares in the last quarter. Tandem Investment Advisors Inc. boosted its stake in Johnson & Johnson by 4.8% in the first quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock worth $57,867,000 after purchasing an additional 15,003 shares in the last quarter. Finally, Tcwp LLC acquired a new position in Johnson & Johnson in the first quarter worth $946,000. Institutional investors and hedge funds own 68.59% of the company’s stock.

Johnson & Johnson Trading Up 0.8 %

NYSE JNJ opened at $176.20 on Monday. The stock has a 50-day simple moving average of $167.84 and a 200 day simple moving average of $171.29. The company has a market capitalization of $460.67 billion, a PE ratio of 24.54, a P/E/G ratio of 3.49 and a beta of 0.57. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The business had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.60 earnings per share. Research analysts forecast that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be paid a $1.13 dividend. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 dividend on an annualized basis and a yield of 2.57%. Johnson & Johnson’s payout ratio is 62.95%.

Johnson & Johnson declared that its board has authorized a stock repurchase program on Wednesday, September 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to repurchase up to 1.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Sanford C. Bernstein reduced their price objective on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Morgan Stanley reduced their price objective on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 19th. Raymond James reduced their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. StockNews.com began coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Finally, Citigroup dropped their target price on Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. Seven equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $181.33.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,410 shares of the business’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total value of $2,845,822.20. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,410 shares of the business’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total value of $2,845,822.20. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 118,795 shares of company stock valued at $20,230,174. Company insiders own 0.35% of the company’s stock.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.